Skip to main content
Log in

Radiotherapy for elderly patients and cetuximab, a monocentric study

  • Head and Neck
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012. Median follow-up was 22 months. Median age was 74 years (70–86). Median performance status was 1 (0–2). Female/male sex ratio was 0.34. Tumor sites were: oropharynx (57.1 %), larynx (20 %), hypopharynx (14.3 %), oral cavity (2.9 %), nasopharynx (2.9 %), and lymph node with unknown primary (2.9 %). Using TNM classification, tumors were: T1 (5.9 %), T2 (35.3 %), T3 (35.3 %), T4 (22.9 %), N0 (28.6 %), N1 (8.6 %), N2 (48.6 %), and N3 (14.3 %). Median radiotherapy dose was 70 (60–70). RT was interrupted in 94 % of patients and the dose of cetuximab was reduced in 29 %. Median survivals were, respectively: 49 months for overall survival (standard error (SE) = 8) and 32 months for relapse-free survival (SE = 10). Two-year local–regional relapse and metastatic relapse-free survivals were, respectively, 59 % (SE = 10) and 74 % (SE = 10). Concomitant radiotherapy and cetuximab seem to be an effective therapy in the elderly population with encouraging results similar to the literature concerning its efficacy and toxicity. This treatment should be considered for patients >70 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. United Nation—Population Division—Departments of Economic and Social Affairs—Population AGEING 2002 (Internet) (cité 17 Déc 2015). Disponible sur: http://www.un.org/esa/population/publications/ageing/Graph.pdf

  2. Balducci L, Beghe’ C (2001) Cancer and age in the USA. Crit Rev Oncol Hematol 37(2):137–145

    Article  CAS  PubMed  Google Scholar 

  3. Bernardi D, Barzan L, Franchin G, Cinelli R, Balestreri L, Tirelli U et al (2005) Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Crit Rev Oncol Hematol 53(1):71–80

    Article  PubMed  Google Scholar 

  4. Pignon J-P, Le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol 92(1):4–14

    Article  Google Scholar 

  5. Lionello M, Blandamura S, Lovato A, Franchella S, Giacomelli L, Ottaviano G et al (2013) A high nuclear nm23-H1 expression is associated with a better prognosis in elderly patients with laryngeal carcinoma. Acta Otolaryngol (Stockh) 133(8):874–880

    Article  CAS  Google Scholar 

  6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

    Article  CAS  PubMed  Google Scholar 

  7. Lovato A, Marioni G, Manzato E, Staffieri C, Giacomelli L, Ralli G et al (2014) Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23-H1 and CD105) and pN+ status. Eur Arch Otorhinolaryngol 272(11):3417–3424

    Article  PubMed  Google Scholar 

  8. Sobin LH, Gospodarowicz MK, Wittekind C (2014) TNM classification of malignant tumours, 7th edn (Internet) (cité 31 Juill 2014). Disponible sur: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1444332414.html

  9. Protocol Development, CTEP (Internet) (cité 4 Juill 2016). Disponible sur: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

  10. Sarris EG, Harrington KJ, Saif MW, Syrigos KN (2014) Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev 40(3):465–475

    Article  PubMed  Google Scholar 

  11. Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P et al (2015) Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol

  12. Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V et al (2015) Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol 96(1):167–182

    Article  PubMed  Google Scholar 

  13. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ortholan C, Benezery K, Dassonville O, Poissonnet G, Bozec A, Guiochet N et al (2011) A specific approach for elderly patients with head and neck cancer. Anticancer Drugs 22(7):647–655

    Article  CAS  PubMed  Google Scholar 

  15. Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H et al (2015) Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol Lond Engl 10:21

    Article  Google Scholar 

  16. Shaw SM, Flowers H, O’Sullivan B, Hope A, Liu LWC, Martino R (2015) The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia 30(2):152–175

    Article  PubMed  Google Scholar 

  17. Montero PH, Patel SG (2015) Cancer of the oral cavity. Surg Oncol Clin N Am 24(3):491–508

    Article  PubMed  PubMed Central  Google Scholar 

  18. González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother J Gt Cancer Cent Pozn Pol Soc Radiat Oncol 20(5):328–339

    Google Scholar 

  19. Fowler JF, Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23(2):457–467

    Article  CAS  PubMed  Google Scholar 

  20. Ho C (2010) Cetuximab in locally advanced head-and-neck cancer: defining the population. Curr Oncol 17(4):48–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kataria T, Gupta D, Bisht SS, Goyal S, Basu T, Srivastava A et al (2015) Chemoradiation in elderly patients with head and neck cancers: a single institution experience. Am J Otolaryngol 36(2):117–121

    Article  PubMed  Google Scholar 

  22. Jensen AD, Bergmann ZP, Garcia-Huttenlocher H, Freier K, Debus J, Münter MW (2010) Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck(SCCHN) in the elderly and multi-morbid patient: a single-centre experience. Head Neck Oncol 2:34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karen Benezery.

Ethics declarations

Conflict of interest

The authors declare that they do not have conflict of interests.

Research involving humans

This retrospective study received approval by the local ethics committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falk, A.T., Hébert, C., Tran, A. et al. Radiotherapy for elderly patients and cetuximab, a monocentric study. Eur Arch Otorhinolaryngol 274, 1061–1065 (2017). https://doi.org/10.1007/s00405-016-4336-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-016-4336-3

Keywords

Navigation